Futuretech Ii Acquisition CORP

FutureTech II Acquisition Corp. has successfully extended its business combination deadline by nine months, moving it from August 18, 2026, to May 18, 2027, following stockholder approval.

FutureTech II Acquisition Corp. announced a restatement of previously issued financial statements for multiple periods due to identified errors and misstatements.

FutureTech II Acquisition Corp.'s independent auditor, Adeptus Partners LLC, resigned effective January 12, 2026, citing material weaknesses and expressing substantial doubt about the company's ability to continue as a going concern.

FutureTech II Acquisition Corp. has terminated zero-interest convertible notes totaling $1.025 million with six investors, effective November 8, 2025, with no funds having been advanced to the company.

FutureTech II Acquisition Corp. provides an update on its merger with Longevity Biomedical, Inc., including a waiver allowing target Aegeria Soft Tissue, LLC to solicit alternative acquisition proposals.

FutureTech II Acquisition Corp. stockholders approved an extension of the deadline to complete an initial business combination until August 18, 2026.

FutureTech II Acquisition Corp. reports significant net losses and liquidity challenges, while progressing with its proposed business combination with Longevity Biomedical, Inc. despite a Nasdaq delisting and ongoing operational hurdles.

FutureTech II Acquisition Corp.'s Q1 2025 report reveals a net loss, ongoing efforts to complete a business combination with Longevity Biomedical, and challenges with Nasdaq listing compliance.

FutureTech II Acquisition Corp. reports a net loss for Q3 2024 and is working to complete a business combination with Longevity Biomedical, Inc. while addressing Nasdaq compliance issues.

FutureTech II Acquisition Corp. has filed an amended quarterly report to correct accounting errors related to due from sponsor, common stock redemption, and notes payable.

FutureTech II Acquisition Corp. files an amended quarterly report to correct accounting errors related to sponsor dues, common stock redemption, and notes payable.

FutureTech II Acquisition Corp. has restated its Q3 2023 financials due to material accounting errors, impacting redemption calculations and other financial metrics.

FutureTech II Acquisition Corp.'s 10-K filing outlines the company's share structure, warrant details, and ongoing efforts to complete a business combination, including a merger agreement with Longevity Biomedical Inc.

FutureTech II Acquisition Corp. has filed an amended annual report to correct errors related to extension loans and overpayments in share redemptions.

FutureTech II Acquisition Corp.'s 10-K filing outlines its capital structure, including Class A and Class B common stock, warrants, and key governance provisions.

Ray Lei Chen, CEO and CFO of FutureTech II Acquisition Corp., converted 380,000 shares of Class B Common Stock into 380,000 shares of Class A Common Stock on February 4, 2025.

Zachary C. Radu, a director and indirect owner of FutureTech II Acquisition Corp., converted 2,445,000 shares of Class B Common Stock to Class A Common Stock on February 4, 2025.

Director Neil Bush converted 10,000 shares of Class B Common Stock to 10,000 shares of Class A Common Stock in FutureTech II Acquisition Corp.

Director Jeffrey Alan Moseley converted 10,000 shares of Class B Common Stock to 10,000 shares of Class A Common Stock in FutureTech II Acquisition Corp.

Aroop Zutshi, a former director of FutureTech II Acquisition Corp., converted 10,000 shares of Class B Common Stock into 10,000 shares of Class A Common Stock on February 4, 2025.

Michael William Greenall, former CFO and director of FutureTech II Acquisition Corp., converted 20,000 shares of Class B Common Stock into 20,000 shares of Class A Common Stock on February 4, 2025.

FutureTech II Acquisition Corp. is holding a special meeting on August 13, 2026, to vote on extending its deadline to complete a business combination by nine months to May 18, 2027.

FutureTech II Acquisition Corp. seeks stockholder approval to extend its business combination deadline to August 18, 2026, to complete its merger with Longevity Biomedical, Inc.

FutureTech II Acquisition Corp. has amended its proxy statement to remove the $50,000 cap on extension payments and has postponed its special meeting to November 18, 2024.

FutureTech II Acquisition Corp. is seeking stockholder approval to extend the deadline for completing a business combination and to amend the charter to allow for earlier conversion of founder shares to maintain Nasdaq compliance.

FutureTech II Acquisition Corp. is seeking stockholder approval to extend its business combination deadline and amend founder share conversion terms to maintain its Nasdaq listing and proceed with its merger with Longevity Biomedical, Inc.

Walleye Capital LLC has filed an amended Schedule 13G, indicating it no longer holds any beneficial ownership in Futuretech II Acquisition Corp.'s Class A Common stock as of March 31, 2025.

Hudson Bay Capital Management LP and Sander Gerber have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 4.65% of FutureTech II Acquisition Corp.'s Class A Common Stock.

Calamos Market Neutral Income Fund has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 11.6% in FutureTech II Acquisition Corp.'s Class A shares as of April 30, 2025.

Calamos Market Neutral Income Fund has reported a passive 11.7% beneficial ownership stake in FutureTech II Acquisition Corp.'s Class A securities.

Calamos Market Neutral Income Fund has reported a passive 11.7% beneficial ownership stake in FutureTech II Acquisition Corp., holding 500,000 Class A shares as of December 31, 2024.

Walleye Capital LLC has disclosed a 5.44% beneficial ownership stake in Futuretech II Acquisition Corp.'s Class A Common stock as of December 31, 2024.